Remove Antibody Remove Bacteria Remove Life Science Remove Protein
article thumbnail

2021 Year in Review: Leveraging New Technologies to Drive Innovation in the Life Sciences

XTalks

Xtalks is taking a look at some of the major stories and innovations of the year in the life sciences, many of which were driven by new, emerging and improved technologies. The year 2021 was all about continuing innovations in the life sciences. Life Science Innovations: Malaria and Influenza Vaccines.

article thumbnail

2020 Year in Review: COVID-19, CRISPR and Immunotherapies Define the Year for the Life Sciences

XTalks

The pandemic propelled the life science and healthcare sectors onto center stage, and they rose to the occasion against the most unprecedented health challenge in recent times. While COVID-19 has undoubtedly been the biggest story in the life science industry in 2020, it was a busy and positive year in many other areas.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

How Nanobodies from Cormac the Llama Could Prevent COVID-19 Infection

XTalks

Researchers at the National Institutes of Health (NIH) in the US have isolated small antibodies called “nanobodies” from a llama named Cormac that can block the SARS-CoV-2 coronavirus. Nanobodies are about a quarter of the size, and approximately one tenth of the weight, of a typical human antibody.

Antibody 105
article thumbnail

Global drug discovery hotspots: Glasgow, UK

Drug Discovery World

The new hub will become a part of the already thriving life sciences sector in the Glasgow area, most of which is centred around the university, the Cancer Research UK Scotland Institute and the BioCity cluster, making Glasgow and its surrounds one of the most important regions for drug discovery and development in the UK.

Drugs 75
article thumbnail

Minervax raises €47.4m in Series B funding round for GBS shot

pharmaphorum

On the back of phase 1b data the Copenhagen-based biotech said it had brought in new investors Sanofi Ventures, Adjuvant Capital and Industrifonden along with existing investors Novo Holdings, REPAIR Impact, Sunstone Life Science Ventures and LF Investment.

article thumbnail

Cyfendus Anthrax Vaccine Wins FDA Approval

XTalks

The bacteria usually enter the body through wounds, but infection can also occur through contaminated meat or inhalation of spores. Cyfendus functions by stimulating the production of antibodies targeted against the protective antigen protein. Anthrax is a rare, yet severe disease caused by the bacterium B. Overall, 66.3

article thumbnail

FDA Approves GSK’s Benlysta (belimumab) for Pediatric Patients with Lupus Nephritis

XTalks

Benlysta (belimumab) is a biologic therapy, a human monoclonal antibody. Autoreactive B cells release antibodies like other B cells do, except they release autoantibodies. The autoantibodies do not fight actual infection or bacteria, but rather the normal tissue in the body. How Benlysta (belimumab) Works.